about
Structural and biochemical characterization of the folyl-poly-γ-l-glutamate hydrolyzing activity of human glutamate carboxypeptidase IIStructural basis for drug and substrate specificity exhibited by FIV encoding a chimeric FIV/HIV proteaseSynthesis, X-ray Analysis, and Biological Evaluation of a New Class of Stereopure Lactam-Based HIV-1 Protease InhibitorsGS-8374, a Prototype Phosphonate-Containing Inhibitor of HIV-1 Protease, Effectively Inhibits Protease Mutants with Amino Acid InsertionsThermodynamic and structural analysis of HIV protease resistance to darunavir - analysis of heavily mutated patient-derived HIV-1 proteasesInhibitor and substrate binding induced stability of HIV-1 protease against sequential dissociation and unfolding revealed by high pressure spectroscopy and kineticsDesigning Fluorescent Peptide Sensors with Dual Specificity for the Detection of HIV-1 ProteaseEffects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists' arsenal.Synthetic, structural mimetics of the β-hairpin flap of HIV-1 protease inhibit enzyme function.Clinically relevant drug-drug interactions between antiretrovirals and antifungalsOral Lopinavir Use and Human Papillomavirus Infection in HIV-Positive Women.HIV-1 Protease Dimerization Dynamics Reveals a Transient Druggable Binding Pocket at the Interface.Selection of drug-resistant feline immunodeficiency virus (FIV) encoding FIV/HIV chimeric protease in the presence of HIV-specific protease inhibitorsEffect of polarization on HIV-1protease and fluoro-substituted inhibitors binding energies by large scale molecular dynamics simulations.Metallacarboranes and their interactions: theoretical insights and their applicability.Chemical biology based on target-selective degradation of proteins and carbohydrates using light-activatable organic molecules.Recent patents and emerging therapeutics for HIV infections: a focus on protease inhibitors.Special issue: retroviral enzymes.Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System.Chemical methods for degradation of target proteins using designed light-activatable organic molecules.Target-selective photodegradation of HIV-1 protease and inhibition of HIV-1 replication in living cells by designed fullerene-sugar hybrids.Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies.Room Temperature Neutron Crystallography of Drug Resistant HIV-1 Protease Uncovers Limitations of X-ray Structural Analysis at 100 K.Molecular basis and potential activity of HIV-1 reverse transcriptase toward trimethylamine-based compounds.Developing HIV-1 Protease Inhibitors through Stereospecific Reactions in Protein Crystals.Triggering HIV polyprotein processing by light using rapid photodegradation of a tight-binding protease inhibitor.Induced maturation of human immunodeficiency virus.Ion specific effects of alkali cations on the catalytic activity of HIV-1 protease.HIV-1 integrase inhibition: looking at cofactor interactions.Proteases and protease inhibitors in infectious diseases.Flap Dynamics in Aspartic Proteases: A Computational Perspective.Nonstructural Proteins of Alphavirus-Potential Targets for Drug Development.Validation of simultaneous quantitative method of HIV protease inhibitors atazanavir, darunavir and ritonavir in human plasma by UPLC-MS/MS.Development of peptide inhibitors of HIV transmission.
P2860
Q24298320-CE4DBF56-AAA8-4559-9774-47EAE5B6C122Q27668150-77F66BDE-FCD6-42BD-B06E-079671C81040Q27677537-5E954915-2EC9-4F9E-979C-5C8C8002C797Q27681100-4B0E3446-37C3-4910-A663-55EFA8E7A0D3Q27690132-20DF0762-5833-442E-BA6F-F3F7E8FBB91DQ33464456-5E2ED6B7-8893-4FFC-9E8D-943C97F6CD4AQ33642827-6201E295-2A05-4F41-89AB-7279931D58E6Q35650944-A293D908-A442-4175-BCDE-3A9D7F5369EFQ35653603-21CB0230-87CE-4A3E-A1DE-757C7E00BAE5Q35810756-660E5D74-5B6D-4BF1-BC6C-9D73D770978AQ35892563-1FC9B07D-3173-4DF6-9CC8-08BEE23967B4Q36068987-AA41EFF2-A2D7-47D8-9ECD-D7EBAC19B1CAQ36392939-F42A6E8A-D8CF-4E40-89D1-00CBFD070152Q37036823-7B40AAD5-8A42-49AA-B782-32C2C2C7DE37Q37622781-8C91DAE2-132A-4EE3-9CEA-328C663ACC28Q37984003-07534EF8-7CE1-4FE9-BB44-57CE6A80D0DEQ38068131-F6DC4D56-69D1-448B-9A37-8A4F9A8368F9Q38162985-CF03992D-E97E-42DC-A4E6-FED846416F5BQ38632850-B786EF2A-68CA-4F23-9853-B2A5E6F2EA98Q38814591-BCBB959D-E08F-4EEC-B69C-00EE97A786F7Q39324111-BACB478D-6875-40BF-B267-8201BA649FF0Q39387906-2C69A38A-4E8B-44F7-813D-85E746D003F7Q40171626-67374FF8-CAC8-4E48-BFC2-E31409FBF569Q40336902-B03EE4D0-DA6F-41CB-883D-514A53E4B701Q40446517-E246A6DD-751C-4518-A2F5-B5A95F2A9922Q40467926-75FF3D41-D51B-4693-9F20-05E8487C809EQ41442854-E5DE33F2-B198-4396-9D83-E9F1FB8292F6Q41735307-2FA6849A-10A5-45FE-89CC-19B2518B25D3Q42288628-823B87F1-9076-4C7B-84E9-801D8D7BEEB3Q43714820-6C662B16-2DC3-498D-BBA8-DAED8B8D2ACDQ47576680-F498E7BF-21B0-46FD-A623-8D3E68DD0F77Q47948025-084CBD4D-1AFE-4504-AA83-C5D913AF77D2Q50099898-F9741C2E-072C-479A-B67B-4E86B6748603Q51848081-FE5AB00E-FC50-4A58-8F1F-9E04EE96223AQ55317261-6913EC3C-F8B1-45B5-A805-B3C167B0C3A1
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Current and Novel Inhibitors of HIV Protease
@ast
Current and Novel Inhibitors of HIV Protease
@en
type
label
Current and Novel Inhibitors of HIV Protease
@ast
Current and Novel Inhibitors of HIV Protease
@en
prefLabel
Current and Novel Inhibitors of HIV Protease
@ast
Current and Novel Inhibitors of HIV Protease
@en
P2860
P356
P1433
P1476
Current and Novel Inhibitors of HIV Protease
@en
P2093
Jana Pokorná
Ladislav Machala
P2860
P304
P356
10.3390/V1031209
P577
2009-12-11T00:00:00Z